Targeted therapies for treatment of recurrent ovarian cancer.
نویسندگان
چکیده
Ovarian cancer remains the leading cause of death among women with gynecologic malignancies in the United States. Most women with epithelial ovarian cancer present with advanced disease. Despite good response rates to initial surgery and chemotherapy, the majority of patients experience relapse and ultimately die of their disease. A better understanding of the molecular differences underlying the histologic subtypes of epithelial ovarian cancer has led to recent advances in targeted therapeutic strategies. Here we review the most promising targeted therapeutics currently being used for the treatment of recurrent ovarian cancer.
منابع مشابه
Systemic Targeted Alpha Radiotherapy for Cancer
Background: The fundamental principles of internal targeted alpha therapy for cancer were established many decades ago.The high linear energy transfer (LET) of alpha radiation to the targeted cancer cellscauses double strand breaks in DNA. At the same time, the short range radiation spares adjacent normal tissues. This targeted approach complements conventional external beam radiotherapy and ch...
متن کاملTargeted Therapies in Epithelial Ovarian Cancer
Molecularly targeted therapy is relatively new to ovarian cancer despite the unquestionable success with these agents in other solid tumours such as breast and colorectal cancer. Advanced ovarian cancer is chemosensitive and patients can survive several years on treatment. However chemotherapy diminishes in efficacy over time whilst toxicities persist. Newer biological agents that target explic...
متن کاملPalliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
OBJECTIVES To review the available systemic treatments for women with recurrent ovarian cancer. METHODS A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer...
متن کاملNew perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
Ovarian cancer (OC) is the seventh most common cancer in women. Although women diagnosed with OC are usually treated frontline with platinum-based chemotherapy, most of them relapse once treatment is halted. Therefore, maintenance therapies have been developed to secure the response and delay further chemotherapy. There are two established maintenance therapies for women affected by platinum-se...
متن کاملTargeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
With advances in surgical techniques and chemotherapeutic agents, mortality rates from epithelial ovarian cancer (EOC) have slightly decreased over the last 30 years. However, EOC still ranks as the most deadly gynecologic cancer with an overall 5-year survival rate of 45%. Prognosis is especially disappointing for women with platinum-resistant disease, where 80% of patients will fail to respon...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical advances in hematology & oncology : H&O
دوره 12 3 شماره
صفحات -
تاریخ انتشار 2014